Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 63(5): 2114-2130, 2020 03 12.
Article in English | MEDLINE | ID: mdl-31244114

ABSTRACT

ZAK is a new promising target for discovery of drugs with activity against antihypertrophic cardiomyopathy (HCM). A series of 1,2,3-triazole benzenesulfonamides were designed and synthesized as selective ZAK inhibitors. One of these compounds, 6p binds tightly to ZAK protein (Kd = 8.0 nM) and potently suppresses the kinase function of ZAK with single-digit nM (IC50 = 4.0 nM) and exhibits excellent selectivity in a KINOMEscan screening platform against a panel of 403 wild-type kinases. This compound dose dependently blocks p38/GATA-4 and JNK/c-Jun signaling and demonstrates promising in vivo anti-HCM efficacy upon oral administration in a spontaneous hypertensive rat (SHR) model. Compound 6p may serve as a lead compound for new anti-HCM drug discovery.


Subject(s)
Drug Design , MAP Kinase Kinase Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Sulfonamides/pharmacology , Triazoles/pharmacology , Animals , Humans , Leucine Zippers/drug effects , MAP Kinase Kinase Kinases/chemistry , MAP Kinase Kinase Kinases/metabolism , Molecular Docking Simulation , Protein Kinase Inhibitors/blood , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Structure-Activity Relationship , Sulfonamides/blood , Sulfonamides/chemical synthesis , Sulfonamides/chemistry , Triazoles/blood , Triazoles/chemical synthesis , Triazoles/chemistry , Benzenesulfonamides
SELECTION OF CITATIONS
SEARCH DETAIL
...